Search Results - "Wander SA"

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Authors: Bidard FC Barrios C Bianchini G et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2026 Jun 08; Vol. 12 (1). Date of Electronic Publication: 2026 Jun 08.

Publication Type: Letter

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Current landscape of sequencing ADCs in metastatic breast cancer.

Authors: McLaughlin S Ravani LV Moy B et al.

Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2025 Dec 17; Vol. 17, pp. 17588359251396656. Date of Electronic Publication: 2025 Dec 17 (Print Publication: 2025).

Publication Type: Journal Article; Review

Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE

Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.

Authors: Wander SA Weipert CM Cabel L et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2026 Jun 12. Date of Electronic Publication: 2026 Jun 12.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer

Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation.

Authors: Tillman L Pusztai L Wander SA et al.

Source: Cancer cell [Cancer Cell] 2026 Jun 08; Vol. 44 (6), pp. 1099-1107. Date of Electronic Publication: 2026 May 21.

Publication Type: Journal Article; Review

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance.

Authors: Goncalves T Pulido D Perrino CM et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2026 May 19. Date of Electronic Publication: 2026 May 19.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

Authors: Ravani LV Wander SA Kok M et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2026 May 05; Vol. 217 (2). Date of Electronic Publication: 2026 May 05.

Publication Type: Journal Article; Meta-Analysis; Systematic Review; Review

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Authors: Wander SA Lloyd MR Keenan JC et al.

Source: The Lancet. Oncology [Lancet Oncol] 2026 May; Vol. 27 (5), pp. 580-591.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Authors: Bar Y Isakoff SJ Wander SA

Source: JNCI cancer spectrum [JNCI Cancer Spectr] 2025 Sep 01; Vol. 9 (5).

Publication Type: Editorial; Comment

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE; In Process

Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.

Authors: Gomez Marti JL Michaels E Nasrazadani A et al.

Source: Cancer cell [Cancer Cell] 2026 Feb 09; Vol. 44 (2), pp. 254-256.

Publication Type: Journal Article; Comment

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Authors: Lloyd MR Weipert CM Ali A et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jan 06; Vol. 32 (1), pp. 169-178.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Authors: Rugo HS Kaklamani V McArthur H et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jan 06; Vol. 32 (1), pp. 179-187.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.

Authors: Bar Y Fell G Dedeoglu A et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Mar 11; Vol. 11 (1), pp. 27. Date of Electronic Publication: 2025 Mar 11.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Authors: Spring LM Scarpetti L Medford AJ et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Jan 07; Vol. 11 (1), pp. 2. Date of Electronic Publication: 2025 Jan 07.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Diffuse peritoneal inclusion cysts masquerading as disseminated gynecologic malignancy in post-menopausal females: Two cases and a review of the literature.

Authors: Reid HW Wander SA Parra-Herran C et al.

Source: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2025 Nov; Vol. 171 (2), pp. 621-628. Date of Electronic Publication: 2025 Jun 25.

Publication Type: Journal Article; Case Reports; Review

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0210174 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3479 (Electronic) Linking ISSN: 00207292 NLM ISO Abbreviation: Int J Gynaecol Obstet Subsets: MEDLINE

SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine.

Authors: Medford AJ Wander SA

Source: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2025 Nov; Vol. 22 (11), pp. 804-805.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE; In Process

Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.

Authors: Ravani VL Bagheri Z Brufsky AM et al.

Source: Breast cancer research : BCR [Breast Cancer Res] 2025 Oct 23; Vol. 27 (1), pp. 183. Date of Electronic Publication: 2025 Oct 23.

Publication Type: Published Erratum

Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE; In Process

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Authors: Wesolowski R Rugo HS Specht JM et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Oct 01; Vol. 31 (19), pp. 4040-4048.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.

Authors: Keenan JC Medford AJ Dai CS et al.

Source: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jun; Vol. 24 (6), pp. 397-405. Date of Electronic Publication: 2024 Apr 26.

Publication Type: Journal Article; Review

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.

Authors: Ravani LV Bagheri Z Brufsky AM et al.

Source: Breast cancer research : BCR [Breast Cancer Res] 2025 Aug 13; Vol. 27 (1), pp. 146. Date of Electronic Publication: 2025 Aug 13.

Publication Type: Journal Article; Meta-Analysis; Systematic Review; Comparative Study

Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesion.

Authors: Maheswaran S Medford AJ Stryjewski TP et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Aug; Vol. 213 (1), pp. 15-19. Date of Electronic Publication: 2025 Jul 07.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE